Cellular Pharmacology of Tenofovir and Emtricitabine for HIV Prophylaxis (Cell Prep)

Trial Profile

Cellular Pharmacology of Tenofovir and Emtricitabine for HIV Prophylaxis (Cell Prep)

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Dec 2016

At a glance

  • Drugs Emtricitabine (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Efavirenz; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate
  • Indications HIV infections
  • Focus Pharmacokinetics; Therapeutic Use
  • Acronyms Cell Prep
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Aug 2016 Results of this and other four studies published in the Antimicrobial Agents and Chemotherapy (2016).
    • 27 Jun 2016 Results of analysis of endogenous deoxynucleoside triphosphate pool (n=40) published in the Antimicrobial Agents and Chemotherapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top